Biohaven Ltd
BHVN
Company Profile
Business description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Contact
215 Church Street
New HavenCT06510
USAT: +1 203 404-0410
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
239
Stocks News & Analysis
stocks
The secrets of Australia’s Berkshire Hathaway
Washington H. Soul Pattinson is an ASX top 50 stock with one of the best investment track records this country has seen. Yet, most Australians haven’t heard of it, and the company seems to prefer it that way.
stocks
Undervalued ASX share yields over 8%
A potential opportunity for income investors who are interested in high levels of current income.
stocks
Chart of the week: The state of mining's biggest players
This week's chart comes from the Australian equity market outlook for Q4.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,604.10 | 52.90 | 0.62% |
| CAC 40 | 7,597.85 | 15.20 | -0.20% |
| DAX 40 | 19,609.78 | 47.59 | -0.24% |
| Dow JONES (US) | 43,275.91 | 36.86 | 0.09% |
| FTSE 100 | 8,381.44 | 23.19 | 0.28% |
| HKSE | 20,478.46 | 325.65 | -1.57% |
| NASDAQ | 18,489.55 | 115.94 | 0.63% |
| Nikkei 225 | 38,954.60 | 27.15 | -0.07% |
| NZX 50 Index | 12,923.22 | 99.33 | 0.77% |
| S&P 500 | 5,864.67 | 23.20 | 0.40% |
| S&P/ASX 200 | 8,344.40 | 61.20 | 0.74% |
| SSE Composite Index | 3,268.11 | 6.55 | 0.20% |